CONTINUE TO SITE
OR WAIT null SECS
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
KalVista wins grant for DME treatment
KalVista Pharmaceuticals has received a £2.4 million grant to accelerate development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema.